Naya Biosciences, INC 8-K filings

INVO Fertility Inc. has entered into an "Any Market Purchase Agreement" with Alumni Capital LP, establishing a flexible equity financing facility of up to $15 million, potentially extendable to $50 million.

INVO Fertility has acquired full ownership of its Alabama joint venture clinic and resolved Nasdaq listing compliance issues.

INVO Fertility, Inc. has released an updated investor presentation ahead of its participation in the Planet MicroCap Conference.

INVO Fertility, Inc. announced its fiscal year 2025 financial results, reporting a 5% increase in revenue to $6.84 million and a narrowed net loss from continuing operations, while also highlighting recent financing and strategic expansions.

INVO Fertility, Inc. announced that previously issued financial statements for periods ending March 31, June 30, and September 30, 2025, must be restated due to accounting errors related to derivative and debt extinguishment.

INVO Fertility, Inc. has successfully closed the acquisition of Family Beginnings, P.C., expanding its network of fertility care centers and broadening patient access to advanced reproductive care.

INVO Fertility Inc. raised approximately $7.5 million by inducing an institutional investor to exercise existing warrants at a reduced price, issuing new unregistered warrants in return.

INVO Fertility shareholders approved a significant increase in authorized common stock to 250 million shares and the issuance of shares related to a recent private placement.

INVO Fertility, Inc. announced a strategic executive leadership realignment, appointing Terah Krigsvold as CFO and Andrea Goren as Chief Business Officer and CEO of INVO Centers LLC to drive growth.

INVO Fertility, Inc. has signed a definitive agreement to acquire the non-clinical assets of Family Beginnings, P.C., an Indiana-based fertility clinic, for $750,000.

INVO Fertility, Inc. announced a $4.0 million private placement of common stock and warrants to fund acquisitions, debt, and working capital.

INVO Fertility, Inc. announced a 1-for-8 reverse stock split to be effective November 28, 2025, impacting its common stock trading on Nasdaq.

INVO Fertility, Inc. announced its third quarter 2025 financial results, highlighting a 23% increase in total revenue driven by organic clinic growth and INVOcell device expansion.

INVO Fertility, Inc. announced an existing institutional investor exercised an additional investment right, acquiring $500,000 in Series C-2 Convertible Preferred Stock.

INVO Fertility, Inc. announced an institutional investor exercised an additional investment right, injecting $200,000 in cash.

INVO Fertility, Inc. has finalized a $6.01 million settlement with Dr. Elizabeth Pritts and raised $400,000 through an unregistered sale of Series C-2 Convertible Preferred Stock.

INVO FERTILITY, INC. exchanged a senior secured convertible debenture for Series C-2 Convertible Preferred Stock with Five Narrow Lane LP.

INVO Fertility, Inc. entered into a restated third amendment to its revenue loan agreement, increasing minimum interest multiples due to unfulfilled equity investment conditions and adjusting repayment terms.

INVO Fertility, Inc. announced an institutional investor exercised an additional investment right, injecting $200,000 and adjusting the Series C-2 Preferred Stock conversion price to $0.7362 per share.

INVO Fertility, Inc. has dismissed M&K CPAS, PLLC and engaged WithumSmith+Brown, PC as its new independent auditor, with M&K having previously expressed substantial doubt about the company's ability to continue as a going concern.

INVO Fertility, Inc. announced an amendment and exchange of a senior secured convertible debenture, reducing its principal amount by $1.3 million in exchange for preferred stock, and extended key SEC registration deadlines.

INVO Fertility, Inc. reported a 1% revenue increase to a record $1.86 million in Q2 2025, alongside a widened net loss of $3.2 million and an increased Adjusted EBITDA loss.

INVO Fertility, Inc. announced an institutional investor exercised its additional investment right, acquiring $200,000 in Series C-2 Convertible Preferred Stock.

INVO Fertility, Inc. announced an institutional investor's $200,000 additional investment and stockholder approval to increase authorized common stock from 1.39 million to 50 million shares.

INVO Fertility, Inc. has announced a 1-for-3 reverse stock split, effective July 21, 2025, primarily aimed at regaining compliance with Nasdaq's minimum bid price requirement.

INVO Fertility, Inc. has further adjourned its 2025 annual meeting of stockholders to July 23, 2025, to allow for a vote on proposal 3.

INVO Fertility, Inc. has amended the terms of its Series C-2 Convertible Preferred Stock and entered into new agreements with an institutional investor, involving a debt-to-equity exchange and a cash investment, under highly dilutive conditions.

INVO Fertility, Inc. held its 2025 annual meeting, electing all director nominees and approving several stock issuance proposals, but adjourned a critical vote to increase authorized common stock until July 9, 2025, to solicit further votes.

INVO Fertility, Inc. has completed the divestiture of a majority of its holdings in NAYA Therapeutics Inc., a move expected to streamline operations but resulting in a significant pro forma reduction in total assets and a shift to negative equity.

INVO Fertility, Inc. announced a series of complex financial restructuring agreements, including the partial divestiture of its NAYA Therapeutics subsidiary, amendments to preferred stock and convertible debentures, and a key management resignation, all occurring amidst existing defaults on prior obligations.